Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States... Show more
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where XERS advanced for three days, in of 239 cases, the price rose further within the following month. The odds of a continued upward trend are .
XERS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 198 cases where XERS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for XERS moved out of overbought territory on September 08, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 62 cases where XERS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on September 09, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on XERS as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for XERS turned negative on August 29, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XERS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (20.524). P/E Ratio (0.000) is within average values for comparable stocks, (53.276). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.172). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (4.645) is also within normal values, averaging (337.274).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. XERS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
a developer of ready-to-use, liquid-stable injectables
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
MYITX | 9.76 | 0.03 | +0.31% |
NYLI WMC International Research Eq Cl A | |||
FCCVX | 38.21 | N/A | N/A |
Fidelity Advisor Convertible Secs C | |||
JNRRX | 59.86 | N/A | N/A |
PGIM Jennison Natural Resources R | |||
PRDSX | 46.79 | N/A | N/A |
T. Rowe Price Integrated US Sm Gr Eq | |||
SNWAX | 69.31 | N/A | N/A |
Easterly Snow Small Cap Value A |
A.I.dvisor indicates that over the last year, XERS has been loosely correlated with MIRM. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then MIRM could also see price increases.
Ticker / NAME | Correlation To XERS | 1D Price Change % | ||
---|---|---|---|---|
XERS | 100% | -2.47% | ||
MIRM - XERS | 50% Loosely correlated | -2.21% | ||
CRNX - XERS | 43% Loosely correlated | +0.80% | ||
AKBA - XERS | 39% Loosely correlated | -1.34% | ||
KROS - XERS | 38% Loosely correlated | -0.63% | ||
TARS - XERS | 38% Loosely correlated | -4.84% | ||
More |